Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization
Cancer Medicine · 2024-01 · 13 (1)
DOI: 10.1002/cam4.6873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 02.01.2024. Verfasst von Rachelle P Mendoza und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Rochester Medical Center, Rochester, New York, USA. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Tumor Suppressor Protein p53, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
TP53 mutation is present in about 50.8% of lung adenocarcinomas, frequently in combination with other genetic alterations. However, a rare subset harbors the TP53 mutation alone.
Methods
Next‐generation sequencing was performed in 844 lung adenocarcinomas diagnosed by fine needle aspiration. Fourteen cases (1.7%) showed isolated TP53 alteration and were subjected to a comprehensive analysis.
Results
The average age at diagnosis was 65.7 years (range 48–79); 9 males and 5 females. All were smokers with an average pack‐year of 40.7 (range 10–70). Ten had metastases, mostly in the brain ( n = 4) and pleura ( n = 4). After a follow‐up period of up to 102 months, 9 died, 3 were alive free of disease, 1 was alive with disease, and 1 was lost to follow‐up. The median survival was 12.2 months. Most tumors exhibited poor differentiation, composed of solid sheets with moderate to severe atypia, increased mitotic activity, and necrotic background. Half were positive for TTF‐1 and showed p53 overexpression. PD‐L1 was positive in 5 cases. Most alterations were missense mutations in exons 5–8, and this mutation type was associated with p53 overexpression. Tumors with combined missense mutation and truncated protein had higher PD‐L1 expression along with a trend towards an increase in tumor mutational burden (TMB). CEBPA deletion of undetermined significance was the most common copy number alteration.
Conclusion
Isolated TP53 mutation was seen in association with smoking, high‐grade cytomorphologic features, adverse prognosis, and recurrent CEBPA deletions. These tumors tend to have strong PD‐L1 expression and high TMB, suggesting potential benefit from immune checkpoint inhibitors. Hence, the recognition of this molecular group has prognostic and therapeutic implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Rochester Medical Center, Rochester, New York, USA.
- Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Pathology, The University of Chicago Hospitals, Chicago, Illinois, USA.
- Department of Pathology, OSF Little Company of Mary Medical Center, Evergreen Park, Illinois, USA.
ORCID-Profile: Rachelle P Mendoza
Zitieren
APA
Mendoza, R. P., Chen-Yost, H. I., Wanjari, P., Wang, P., Symes, E., Johnson, D. N., Reeves, W., Mueller, J., Antic, T., & Biernacka, A. (2024). Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization. Cancer Medicine, 13(1). https://doi.org/10.1002/cam4.6873
Vancouver
Mendoza RP, Chen-Yost HI, Wanjari P, Wang P, Symes E, Johnson DN, et al. Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization. Cancer Medicine. 2024;13(1). doi:10.1002/cam4.6873
BibTeX
@article{Mendoza2024,
author = {Mendoza, Rachelle P and Chen-Yost, Heather I-Hsuan and Wanjari, Pankhuri and Wang, Peng and Symes, Emily and Johnson, Daniel N and Reeves, Ward and Mueller, Jeffrey and Antic, Tatjana and Biernacka, Anna},
title = {Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {1},
doi = {10.1002/cam4.6873}
}
EUVIMED